We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
76
Beam Therapeutics
BEAM
$2.71B
$32.4M 0.37%
+396,821
New +$19.5M
ATRC icon
77
AtriCure
ATRC
$1.76B
$31M 0.35%
+556,374
New +$24.1M
VEEV icon
78
Veeva Systems
VEEV
$32.1B
$30.5M 0.35%
111,941
+16,574
+17% +$4.64M
HCM icon
79
HUTCHMED
HCM
$1.95B
$30.3M 0.35%
947,674
– –
NEO icon
80
NeoGenomics
NEO
$1.85B
$29.5M 0.34%
548,446
+121,554
+28% +$5.49M
MASI
81
DELISTED
Masimo
MASI
$28.9M 0.33%
107,824
+5,671
+6% +$1.41M
ONEM
82
DELISTED
1Life Healthcare
ONEM
$27.8M 0.32%
637,553
+168,989
+36% +$5.77M
HZNP
83
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$27.8M 0.32%
380,200
+302,800
+391% +$22.5M
ONC
84
BeOne Medicines Ltd
ONC
$32.2B
$27.7M 0.32%
107,100
+67,700
+172% +$18.6M
HCAT icon
85
Health Catalyst
HCAT
$160M
$27M 0.31%
620,210
+98,314
+19% +$3.63M
EXAS
86
DELISTED
Exact Sciences
EXAS
$25.8M 0.3%
195,000
-109,490
-36% -$13.2M
PEN icon
87
Penumbra
PEN
$12.5B
$25.8M 0.3%
147,495
+26,301
+22% +$5.76M
PHR icon
88
Phreesia
PHR
$660M
$25.6M 0.29%
472,720
+45,764
+11% +$1.96M
CDNA icon
89
CareDx
CDNA
$1.98B
$24.9M 0.29%
343,983
-771,920
-69% -$44.7M
AMWL icon
90
American Well
AMWL
$210M
$23.9M 0.27%
47,108
+28,115
+148% +$16.3M
KZR
91
DELISTED
Kezar Life Sciences
KZR
$23.7M 0.27%
453,315
– –
SILK
92
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$23.5M 0.27%
372,890
+72,271
+24% +$4.48M
IRTC icon
93
iRhythm Holdings
IRTC
$3.66B
$23.4M 0.27%
98,602
+8,084
+9% +$1.84M
TXG icon
94
10x Genomics
TXG
$5.49B
$23.4M 0.27%
165,123
+11,134
+7% +$1.62M
GH icon
95
Guardant Health
GH
$19.6B
$23.1M 0.26%
179,241
+16,858
+10% +$1.94M
NVRO
96
DELISTED
NEVRO CORP.
NVRO
$22.6M 0.26%
130,402
+9,833
+8% +$1.59M
RMD icon
97
ResMed
RMD
$28.8B
$21M 0.24%
98,975
+21,170
+27% +$4.22M
AMED
98
DELISTED
Amedisys
AMED
$20.9M 0.24%
71,190
+9,339
+15% +$2.39M
TMO icon
99
Thermo Fisher Scientific
TMO
$196B
$20.7M 0.24%
44,455
-26,410
-37% -$12.4M
WVE icon
100
Wave Life Sciences
WVE
$1.1B
$20.5M 0.23%
2,602,858
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.